←
eChinaHealth4,304 posts
eChinaHealth avatar

eChinaHealth

@eChinaHealth

Covers China healthcare and pharma market with digital platform & media, conferences & events, social network & community, and medical education & training

◷ Joined August 2020▧ 2,201 Photos and videos
eChinaHealth avatar
eChinaHealth@eChinaHealth·Nov 16

2026 China Anti-Cancer Association Annual Meeting opened in Changsha, China, bringing together experts from 40 countries to advance integrative cancer care, precision medicine, and global collaboration. eChinaHealth News reports on the opening of #CCHIO: mp.weixin.qq.com/s/OK5opcAjV…

Post attachmentPost attachmentPost attachmentPost attachment
eChinaHealth avatar
eChinaHealth@eChinaHealth·Nov 12

A busy start for the @AACR booth at the 2026 Chinese Anti-Cancer Association Annual Meeting! Great to see strong interest from Chinese cancer research professionals in AACR’s research, publications, and programs. Proudly managed by eChinaHealth in collaboration with AACR. #Cancer

Post attachmentPost attachment
eChinaHealth avatar
eChinaHealth@eChinaHealth·Nov 12

“AACR China,” operated by eChinaHealth under agreement with @AACR, posted a Chinese-language story on 91 years of AACR–China ties—from a 1935 paper by Chinese researchers to @AACRPres Keith Flaherty’s visit to Changsha for the Chinese Anti-Cancer Assoc Annual Meeting. @CD_AACR

Post attachmentPost attachmentPost attachmentPost attachment
Elizabeth McKenna avatar
⟳ eChinaHealth retweeted
Elizabeth McKenna@ElizSMcKenna·Nov 11

A great blog post on the first-ever @AACR journal article from China that also mentions two new pieces out in @CD_AACR this week for the CCHIO meeting in Changsha, which will feature a Cancer Discovery Symposium with several recent authors speaking 👇🏻

AACR@AACRNov 11

Before @CR_AACR, there was The American Journal of Cancer, and 91 years ago, that forerunner to Cancer Research published AACR’s first paper from Chinese researchers. Learn more about the paper and AACR’s collaborative history with China on the #AACRBlog: brnw.ch/21x73oi

Post attachment
eChinaHealth avatar
eChinaHealth@eChinaHealth·Nov 11

At ESMO 2026, eChinaHealth interviewed Dr. Nathan Pennell, SVP and Global Head of Oncology Medical Affairs at BMS, on the global development strategy, clinical potential, and future of iza-bren (EGFR×HER3 #bispecific ADC). Phase III #PANKU-Lung01 results: LBA71. @bmsnews #ADC

7:35
eChinaHealth avatar
eChinaHealth@eChinaHealth·Nov 11

At ESMO 2026 Madrid, eChinaHealth interviewed Prof. Li Zhang, lead PI of Phase III PANKU-Lung01, on iza-bren (EGFR×HER3 bispecific ADC) in EGFR-TKI-resistant NSCLC. Median PFS: 11.1 vs 5.7 months (HR 0.40). LBA71 | Published in The Lancet #PANKI #EGFR #HER3 #LungCancer #ADC

9:10
eChinaHealth avatar
eChinaHealth@eChinaHealth·Nov 11

How can China’s positive clinical data accelerate global drug development? At ESMO26 Madrid, eChinaHealth interviewed Dr. Dimitrios Zardavas of BMS on the global development of iza-bren, indication prioritization, and challenges in a rapidly evolving oncology landscape. @bmsnews

5:28
eChinaHealth avatar
eChinaHealth@eChinaHealth·Nov 10

eChinaHealth interviewed Prof. Binghe Xu, lead PI of PANKU-Breast01, at ESMO 2026 Madrid on iza-bren (EGFR×HER3 bispecific ADC) and its potential in HR+/HER2− breast cancer. Phase III results were presented as LBA50 and published in The #Lancet. #iza #bren #ADC #breastcancer

7:18
eChinaHealth avatar
eChinaHealth@eChinaHealth·Nov 10

Published by CACA and Tianjin Medical University, Cancer Biology & Medicine focuses on advancing translational cancer research. The journal is indexed in SCIE (IF=12.4), MEDLINE, and SCOPUS (CiteScore=11.5). Click below to view the content of Issue 10. cancerbiomed.org/content/23/…

Post attachment